中华内分泌代谢杂志
中華內分泌代謝雜誌
중화내분비대사잡지
CHINESE JOURNAL OF ENDOCRINOLOGY AND METABOLISM
2008年
2期
174-177
,共4页
尚立芝%杨宇明%李德祥%韦大文%程晓菊
尚立芝%楊宇明%李德祥%韋大文%程曉菊
상립지%양우명%리덕상%위대문%정효국
抗原%CD26%Ki-67抗原%受体%表皮生长因子%甲状腺肿瘤%诊断%鉴别
抗原%CD26%Ki-67抗原%受體%錶皮生長因子%甲狀腺腫瘤%診斷%鑒彆
항원%CD26%Ki-67항원%수체%표피생장인자%갑상선종류%진단%감별
Antigens%CD26%Ki-67 antigen%Epidermal growth factor receptor%Thyroid neoplasms%Diagnosis%differential
目的 观察CD26、Ki67和表皮生长因子受体(EGFR)在甲状腺良恶性肿瘤中的表达,探讨其鉴别诊断意义,并寻找分化型甲状腺癌标志物.方法 用免疫组化S-P法检测分化型甲状腺癌、腺瘤各50例中CD26、Ki67和EGFR蛋白的表达,并分析它们的相关性.结果 CD26、Ki67和EGFR的阳性表达率、表达强度在腺癌组显著高于腺瘤组、尤其滤泡性腺癌显著高于滤泡性腺瘤组.结论 CD26、Ki67和EGFR的异常表达尤其CD26可能对滤泡上皮起源的甲状腺癌与腺瘤的鉴别诊断、预后判断有参考意义.
目的 觀察CD26、Ki67和錶皮生長因子受體(EGFR)在甲狀腺良噁性腫瘤中的錶達,探討其鑒彆診斷意義,併尋找分化型甲狀腺癌標誌物.方法 用免疫組化S-P法檢測分化型甲狀腺癌、腺瘤各50例中CD26、Ki67和EGFR蛋白的錶達,併分析它們的相關性.結果 CD26、Ki67和EGFR的暘性錶達率、錶達彊度在腺癌組顯著高于腺瘤組、尤其濾泡性腺癌顯著高于濾泡性腺瘤組.結論 CD26、Ki67和EGFR的異常錶達尤其CD26可能對濾泡上皮起源的甲狀腺癌與腺瘤的鑒彆診斷、預後判斷有參攷意義.
목적 관찰CD26、Ki67화표피생장인자수체(EGFR)재갑상선량악성종류중적표체,탐토기감별진단의의,병심조분화형갑상선암표지물.방법 용면역조화S-P법검측분화형갑상선암、선류각50례중CD26、Ki67화EGFR단백적표체,병분석타문적상관성.결과 CD26、Ki67화EGFR적양성표체솔、표체강도재선암조현저고우선류조、우기려포성선암현저고우려포성선류조.결론 CD26、Ki67화EGFR적이상표체우기CD26가능대려포상피기원적갑상선암여선류적감별진단、예후판단유삼고의의.
Objective To observe the expressions of CD26, Ki67 and epidermal growth factor receptor(EGFR) proteins in thyroid neoplasms, to explore their value in differential diagnosis between benign and malignant thyroid neoplasms and to search for molecular marker in well-differentiated thyroid carcinomas.Methods The expressions of CD26,Ki67and EGFR proteins were examined by immunohistochemistry in 50 differentiated thyroid carcinomas (TC) and 50 thyroid adenomas (TA) and their relationships were analyzed.Results The positive rate and expression intensity of CD26,Ki67and EGFR proteins in TC were significantly higher than those in TA, and especially higher in follicular TC than those in follicular TA.Conclusion The abnormal expressions of CD26, Ki67and EGFR proteins appear to be valuable in differential diagnosis and predicting prognosis of thyroid carcinomas, especially CD26 can be used as a diagnostic marker in well-differentiated carcinoma of follicular cell origin.
